Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.

ABSTRACT:

Background

Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence. Longer-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medications and provide HIV-1 protection.

Methods

We conducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vaginal ring containing dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between the ages of 18 and 45 years in Malawi, South Africa, Uganda, and Zimbabwe.

Results

Among the 2629 women who were enrolled, 168 HIV-1 infections

SUBMITTER: Baeten JM 

PROVIDER: S-EPMC4993693 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature